Overcoming binder identification and developability barriers in VH/VHH antibody discovery
28 Apr 2026
Formats & Scaffolds
- How do current VH Tg mouse and/or synthetic library platforms compare to traditional llama immunizations in terms of binder diversity and drug-like properties?
- What are best practices for screening diversity, particularly from immunized animals?
- What have been key challenges in VH / VHH discovery that should be addressed early on in antibody screening and characterization workflows?
- How has AI changed how we’ve addressed these questions, and where has it made an impact?
Industry Expert
